FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/17/2025
Back to search
Official data from USPTO
MANUVEC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MANUVEC
ST13
US500000079363428Class
5, 42, 44
Filing
79363428
Registration
7349629
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
01/17/2025
Trademark type
Word
Nice classes
5, 42, 44
Filing date
01/11/2023
Registration date
04/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/09/2024
Last transaction
01/17/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
26
Owner location
NL
Examiner
STEEL, ALYSSA
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
VectorY B.V.
Representatives
Douglas T. Johnson Miller & Martin PLLC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapynucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapycell therapypharmaceutical preparationsprophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapygene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
Class 42
Scientific and medical researchproduct development and consultancy in the field of biotechnologybiologicsmedical sciencechemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Class 44
Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/01/2025
FIMP
FINAL DISPOSITION PROCESSED
12/31/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/19/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/09/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/23/2024
PUBO
PUBLISHED FOR OPPOSITION
01/23/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/22/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/18/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
12/18/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/18/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
12/18/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/18/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/07/2023
RFNT
REFUSAL PROCESSED BY IB
07/26/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/01/2023
RFRR
REFUSAL PROCESSED BY MPU
07/01/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/20/2023
CNRT
NON-FINAL ACTION WRITTEN
05/19/2023
DOCK
ASSIGNED TO EXAMINER
05/18/2023
MAFR
APPLICATION FILING RECEIPT MAILED
02/28/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/24/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/23/2023
Continuous trademark protection
Get notified about every new filing that threatens MANUVEC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.